Secondly, oncogenic K-RAS activation is known to orchestrate co-activation of several compensatory effector pathways, stimulate signaling bifurcation and cross talk, induce systemic signaling adaptation via feed-forward and feedback mechanisms, synergize cancer network rewiring, and increase tumor cell survival in response to aggressive chemo- and radiation therapies. The gene discussed is KRAS; the disease is cancer.